Literature DB >> 17988363

Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study.

Lars Vedel Kessing1, Lars Søndergård, Kajsa Kvist, Per Kragh Andersen.   

Abstract

OBJECTIVES: To estimate adherence to lithium in a nationwide sample of all patients treated with lithium and to characterize adherence according to gender and age.
METHODS: Adherence to lithium was estimated using data obtained by linking Medicinal Product Statistics with the Danish Medical Register on Vital Statistics, identifying all persons who received lithium among the 5.3 million persons living in Denmark during the period 1995 to 2000 inclusive.
RESULTS: The median time to discontinuation of lithium was 181.0 days [95% confidence interval (CI) 135.7-181.0] and 25% of patients stopped treatment with lithium within 45.2 days. Adherence to lithium was significantly poorer for women (135.7 days; 95% CI 90.5-135.7) than for men (316.7 days; 95% CI 271.4-407.1) and for younger (18-39 years) and older (>or=60 years) patients compared to middle-aged patients.
CONCLUSIONS: The results highlight the need for increased focus on long-term adherence to lithium with intensified psychological support, especially among younger and older female patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17988363     DOI: 10.1111/j.1399-5618.2007.00405.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  12 in total

Review 1.  Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review.

Authors:  Jennifer B Levin; Anna Krivenko; Molly Howland; Rebecca Schlachet; Martha Sajatovic
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 2.  Medication nonadherence in bipolar disorder: a narrative review.

Authors:  Ibrahim Jawad; Stuart Watson; Peter M Haddad; Peter S Talbot; R Hamish McAllister-Williams
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-16

Review 3.  A decision analysis of long-term lithium treatment and the risk of renal failure.

Authors:  U Werneke; M Ott; E Salander Renberg; D Taylor; B Stegmayr
Journal:  Acta Psychiatr Scand       Date:  2012-03-09       Impact factor: 6.392

4.  The effects of centralised and specialised combined pharmacological and psychological intervention compared with decentralised and non-specialised treatment in the early course of severe unipolar and bipolar affective disorders--design of two randomised clinical trials.

Authors:  Lars Vedel Kessing; Hanne Vibe Hansen; Ellen Margrethe Christensen; Henrik Dam; Christian Gluud; Jørn Wetterslev
Journal:  Trials       Date:  2011-02-03       Impact factor: 2.279

5.  Daily electronic self-monitoring of subjective and objective symptoms in bipolar disorder--the MONARCA trial protocol (MONitoring, treAtment and pRediCtion of bipolAr disorder episodes): a randomised controlled single-blind trial.

Authors:  Maria Faurholt-Jepsen; Maj Vinberg; Ellen Margrethe Christensen; Mads Frost; Jakob Bardram; Lars Vedel Kessing
Journal:  BMJ Open       Date:  2013-07-24       Impact factor: 2.692

6.  Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphones--the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial.

Authors:  Maria Faurholt-Jepsen; Maj Vinberg; Mads Frost; Ellen Margrethe Christensen; Jakob Bardram; Lars Vedel Kessing
Journal:  BMC Psychiatry       Date:  2014-11-25       Impact factor: 3.630

7.  Suicide risk in Veterans Health Administration patients with mental health diagnoses initiating lithium or valproate: a historical prospective cohort study.

Authors:  Eric G Smith; Karen L Austin; Hyungjin Myra Kim; Donald R Miller; Susan V Eisen; Cindy L Christiansen; Amy M Kilbourne; Brian C Sauer; John F McCarthy; Marcia Valenstein
Journal:  BMC Psychiatry       Date:  2014-12-17       Impact factor: 3.630

8.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153

9.  Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study.

Authors:  Susanne Kraemer; Anette Minarzyk; Steffen Eppendorfer; Carsten Henneges; Hans-Peter Hundemer; Stefan Wilhelm; Heinz Grunze
Journal:  BMC Psychiatry       Date:  2013-07-17       Impact factor: 3.630

10.  Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder.

Authors:  Maximilian Pilhatsch; Tasha Glenn; Natalie Rasgon; Martin Alda; Kemal Sagduyu; Paul Grof; Rodrigo Munoz; Wendy Marsh; Scott Monteith; Emanuel Severus; Rita Bauer; Philipp Ritter; Peter C Whybrow; Michael Bauer
Journal:  Int J Bipolar Disord       Date:  2018-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.